We report a retrospective review of our institutional data using once daily intravenous (IV) busulfan (Bu) and cyclophosphamide (Cy) and total body irradiation (TBI)/Cy in patients who received allogeneic hematopoietic stem cell transplant (HCT) from January 2000 to December 2006. Bu 3.2 mg/kg IV once daily × 4 days followed by Cy 60 mg/kg IV daily × 2 days was given to 42 patients. Cy 60 mg/kg IV daily for 2 days and fractionated TBI 1200 cGy delivered over 3 days was given to 60 patients. Veno-occlusive disease developed in two patients in the once daily BuCy group and no patients in the TBI/Cy group. The once daily BuCy group had significantly less transplant-related mortality (TRM) than the TBI/Cy group at 100 days (p = 0.047) and better overall survival at 1 year (p = 0.01). This review demonstrates once daily IV BuCy and allogeneic HCT is well tolerated with no unexpected TRM or differences in clinical outcomes.
SantosGWTutschkaPJBrookmeyerR. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med1983; 309(22): 1347–1353.
3.
LuCBraineHGKaizerH. Preliminary results of high dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep1984; 68(5): 711–717.
4.
TutschkaPJCopelanEAKleinJP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood1987; 70(5): 1382–1388.
5.
SociéGCliftRABlaiseD. Busulfan plus cyclophosphamide compared with total- body irradiation plus cyclpphosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood2001; 98(13): 3569–3574.
6.
AnderssonBSMaddenTTranHT. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant2000; 6(5A): 548–554.
7.
AnderssonBSKashyapAGianV. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant2002; 8(3): 145–154.
8.
AnderssonBSThallPFMaddenT. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant2002; 8(9): 477–485.
9.
MaddenTde LimaMThaparN. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant2007; 13(1): 56–64.
10.
AnderssonBSde LimaMThallPF. Once daily i.v. busulfan and fludarabine compares farorably with i.v. busulfan and cyclophosphamide as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant2008; 14(6): 672–684.
11.
RussellJASavoieMLBaloghA. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400cGy total body irradiation, and thymoglobulin. Biol Blood Marrow Transplant2007; 13(7): 814–821.
12.
RussellJATranHTQuinlanD. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant2002; 8(9): 468–476.
13.
BearmanSIAndersonGLMoriM. Venoocclusive disease of the liver: development of a model for predicting fatal outcomes after marrow transplantation. J Clin Oncol1993; 11(9): 1729–1736.
14.
GlucksbergHStorbRFeferA. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation1974; 18(4): 295–304.
15.
FernandezHFTranHTAlbrechtF. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant2002; 8(9): 486–492.
16.
WilliamsCBDaySDReedMD. Dose modification protocol using intravenous busulfan and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant2004; 10(9): 614–623.
17.
HassanMLjungmanPRingdenO. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant2000; 25(9): 915–924.
18.
RyuSLeeJChoiS. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant2007; 13(9): 1095–1105.
19.
MamloukKSaracinoGBerrymanRB. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant2005; 35(8): 747–754.
